Summit Place Financial Advisors LLC Has $3.15 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Summit Place Financial Advisors LLC boosted its holdings in shares of Zoetis Inc. (NYSE:ZTS - Free Report) by 10.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 19,144 shares of the company's stock after buying an additional 1,755 shares during the quarter. Zoetis makes up approximately 1.8% of Summit Place Financial Advisors LLC's investment portfolio, making the stock its 22nd largest position. Summit Place Financial Advisors LLC's holdings in Zoetis were worth $3,152,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in ZTS. Mission Wealth Management LP increased its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company's stock valued at $479,000 after purchasing an additional 59 shares during the last quarter. HUB Investment Partners LLC boosted its holdings in shares of Zoetis by 4.7% during the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company's stock worth $224,000 after acquiring an additional 62 shares during the period. Coppell Advisory Solutions LLC boosted its holdings in shares of Zoetis by 18.0% during the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company's stock worth $68,000 after acquiring an additional 64 shares during the period. Lindbrook Capital LLC increased its stake in shares of Zoetis by 1.8% during the fourth quarter. Lindbrook Capital LLC now owns 3,650 shares of the company's stock worth $595,000 after purchasing an additional 65 shares during the period. Finally, Ironwood Investment Management LLC lifted its holdings in Zoetis by 0.8% during the 4th quarter. Ironwood Investment Management LLC now owns 8,354 shares of the company's stock worth $1,361,000 after purchasing an additional 68 shares during the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the company. Stifel Nicolaus downgraded Zoetis from a "buy" rating to a "hold" rating and dropped their target price for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Wall Street Zen upgraded shares of Zoetis from a "hold" rating to a "buy" rating in a research report on Friday, March 7th. Piper Sandler raised their price objective on Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research note on Monday, May 12th. Finally, UBS Group cut their target price on Zoetis from $189.00 to $170.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Zoetis has an average rating of "Buy" and an average target price of $212.13.

Insider Buying and Selling at Zoetis

In related news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total value of $110,840.00. Following the completion of the sale, the executive vice president directly owned 15,129 shares of the company's stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.18% of the company's stock.

Zoetis Trading Up 0.1%

Shares of ZTS traded up $0.11 during mid-day trading on Thursday, reaching $159.19. 1,375,164 shares of the company were exchanged, compared to its average volume of 2,569,728. The business has a 50 day simple moving average of $160.92 and a two-hundred day simple moving average of $162.32. The company has a debt-to-equity ratio of 1.12, a quick ratio of 1.04 and a current ratio of 1.74. The stock has a market capitalization of $70.87 billion, a PE ratio of 28.58, a PEG ratio of 2.64 and a beta of 0.91. Zoetis Inc. has a 52 week low of $139.70 and a 52 week high of $200.33.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. The firm had revenue of $2.22 billion during the quarter, compared to analyst estimates of $2.20 billion. During the same quarter last year, the business earned $1.38 EPS. The company's revenue was up 1.4% compared to the same quarter last year. On average, analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Stockholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. The ex-dividend date of this dividend is Friday, July 18th. This represents a $2.00 annualized dividend and a dividend yield of 1.26%. Zoetis's dividend payout ratio is currently 35.91%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.